Keros Therapeutics (NASDAQ: KROS) insider transactions
In the twelve months to 10 November 2026, executives and directors of Keros Therapeutics reported 12 open-market sales of 38,625 shares ($522,950) and 6 open-market purchases of 7,000 shares ($75,770), by 10 people, according to the Form 4 filings they submitted to the SEC.
Latest transactions
| Date | Insider | Role | Transaction | Shares | Price | Held after | Filing |
|---|---|---|---|---|---|---|---|
| 18 August 2026 | Newton Charles W. | Director | Open-market sale, 10b5-1 plan | −551 | $10.30 | 12,114 | Form 4 |
| 18 August 2026 | Lerner Lorena Raquel | Chief Scientific Officer | Open-market sale | −3,568 | $10.29 | 27,559 | Form 4 |
| 18 August 2026 | Cho Esther | Chief Legal Officer | Open-market sale | −4,485 | $10.29 | 35,770 | Form 4 |
| 18 August 2026 | Tanini Annita | Corp. Controller & VP, Finance | Open-market sale | −1,224 | $10.29 | 45,144 | Form 4 |
| 17 August 2026 | Bienaime Jean Jacques | Director | Open-market purchase, 10b5-1 plan | +1,000 | $10.27 | 19,592 | Form 4 |
| 15 July 2026 | Bienaime Jean Jacques | Director | Open-market purchase, 10b5-1 plan | +1,000 | $10.61 | 18,592 | Form 4 |
| 1 July 2026 | Prener Anne | Director | Grant or award | +13,786 | — | 13,786 | Form 4 |
| 15 June 2026 | Bienaime Jean Jacques | Director | Open-market purchase, 10b5-1 plan | +1,000 | $10.19 | 17,592 | Form 4 |
| 11 June 2026 | Newton Charles W. | Director | Open-market sale, 10b5-1 plan | −550 | $10.04 | 12,665 | Form 4 |
| 4 June 2026 | Farzan Nima | Director | Open-market sale, 10b5-1 plan | −2,625 | $10.73 | 9,767 | Form 4 |
| 4 June 2026 | Knowles Julius | Director | Open-market sale, 10b5-1 plan | −2,625 | $10.73 | 10,958 | Form 4 |
| 4 June 2026 | Seth Alpna | Director | Open-market sale, 10b5-1 plan | −2,625 | $10.72 | 9,767 | Form 4 |
| 3 June 2026 | Bienaime Jean Jacques | Director | Grant or award | +7,142 | — | 16,592 | Form 4 |
| 3 June 2026 | Gray Mary Ann | Director | Grant or award | +7,142 | — | 12,392 | Form 4 |
| 3 June 2026 | Seth Alpna | Director | Grant or award | +7,142 | — | 12,392 | Form 4 |
| 3 June 2026 | Farzan Nima | Director | Grant or award | +7,142 | — | 12,392 | Form 4 |
| 3 June 2026 | Knowles Julius | Director | Grant or award | +7,142 | — | 13,583 | Form 4 |
| 15 May 2026 | Bienaime Jean Jacques | Director | Open-market purchase, 10b5-1 plan | +1,000 | $10.58 | 9,450 | Form 4 |
| 15 April 2026 | Bienaime Jean Jacques | Director | Open-market purchase, 10b5-1 plan | +1,000 | $11.70 | 8,450 | Form 4 |
| 2 April 2026 | Seehra Jasbir | Chief Executive Officer | Option exercise | +55,000 | $0.30 | 440,708 | Form 4 |
Names appear as in the filing, surname first. A dash in the price column means the filing reports none, as in grants and gifts.
How to read the table
Only open-market purchases and sales are trades the insider chose to make at the market price, and they are the ones counted in the summary above. Grants, option exercises and shares withheld for tax come from pay plans. A sale marked as a 10b5-1 plan was scheduled in advance under a written plan.
Where each row comes from
From the Form 4 that each executive, director or large shareholder must file with the SEC within two business days of a transaction, read up to 10 November 2026. Each row links to its filing on EDGAR. Only transactions in shares are listed, not derivatives, and amended filings are left out. The accounts of the company are on the Keros Therapeutics page; the method, in data sources.
Information prepared from the Form 4 filings submitted to the SEC, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.